Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Sea anemones (Cnidaria, Actiniaria) of Singapore: redescription and taxonomy of Phymanthuspinnulatus Martens in Klunzinger, 1877.

Yap NWL, Tan R, Yong CLX, Tan KS, Huang D.

Zookeys. 2019 Apr 17;840:1-20. doi: 10.3897/zookeys.840.31390. eCollection 2019.

2.

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.

Yong CL, Gathe JC, Knecht G, Orrell C, Mallolas J, Podzamczer D, Trottier B, Zhang W, Sabo JP, Vinisko R, Drulak M, Quinson AM.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):189-195. doi: 10.1080/15284336.2017.1386811.

PMID:
29210627
3.

Koenimbin, a natural dietary compound of Murraya koenigii (L) Spreng: inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44(+)/CD24(-/low)): an in vitro study.

Ahmadipour F, Noordin MI, Mohan S, Arya A, Paydar M, Looi CY, Keong YS, Siyamak EN, Fani S, Firoozi M, Yong CL, Sukari MA, Kamalidehghan B.

Drug Des Devel Ther. 2015 Feb 24;9:1193-208. doi: 10.2147/DDDT.S72127. eCollection 2015.

4.

Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.

Huang F, Moschetti V, Lang B, Halabi A, Petersen-Sylla M, Yong CL, Elgadi M.

Antimicrob Agents Chemother. 2015 Jan;59(1):251-7. doi: 10.1128/AAC.03359-14. Epub 2014 Oct 27.

5.

Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects.

Chen LZ, Rose P, Mao Y, Yong CL, St George R, Huang F, Latli B, Mandarino D, Li Y.

Antimicrob Agents Chemother. 2014;58(4):2369-76. doi: 10.1128/AAC.02156-13. Epub 2014 Feb 10.

6.

Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.

Giaquinto C, Anabwani G, Feiterna-Sperling C, Nuttall J, Mompati K, Königs C, Mensa FJ, Sabo JP, Yong CL, MacGregor TR, Nguyen T, Quinson AM.

Pediatr Infect Dis J. 2014 Jul;33(7):e173-9. doi: 10.1097/INF.0000000000000241.

PMID:
24378938
7.

Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).

Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL, Robinson P, Quinson A.

HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x. Epub 2011 Dec 4.

8.

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.

Duan J, Yong CL, Garneau M, Amad M, Bolger G, De Marte J, Montpetit H, Otis F, Jutras M, Rhéaume M, White PW, Llinàs-Brunet M, Bethell RC, Cordingley MG.

Xenobiotica. 2012 Feb;42(2):164-72. doi: 10.3109/00498254.2011.611546. Epub 2011 Oct 11.

PMID:
21988548
9.

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL, Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM.

Clin Ther. 2011 Sep;33(9):1308-20. doi: 10.1016/j.clinthera.2011.08.003. Epub 2011 Aug 27.

PMID:
21872931
10.

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.

Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, Bogner J, Spencer D, Podzamczer D, Yong CL, Nguyen T, Zhang W, Drulak M, Quinson AM.

Antivir Ther. 2011;16(5):759-69. doi: 10.3851/IMP1803.

PMID:
21817198
11.

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.

Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, White PW, Stern JO, Steinmann G, Yong CL, Kukolj G, Scherer J, Boecher WO.

J Hepatol. 2011 Jun;54(6):1114-22. doi: 10.1016/j.jhep.2010.08.040. Epub 2010 Nov 11.

PMID:
21145839
12.

In vitro-in vivo correlation for nevirapine extended release tablets.

Macha S, Yong CL, Darrington T, Davis MS, MacGregor TR, Castles M, Krill SL.

Biopharm Drug Dispos. 2009 Dec;30(9):542-50. doi: 10.1002/bdd.691.

PMID:
19876936
13.

Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract.

Macha S, Yong CL, MacGregor TR, Castles M, Quinson AM, Rouyrre N, Wilding I.

J Clin Pharmacol. 2009 Dec;49(12):1417-25. doi: 10.1177/0091270009344856. Epub 2009 Sep 30.

PMID:
19793911
14.

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG.

Hepatology. 2005 Apr;41(4):832-5.

PMID:
15732092
15.

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Crönlein J, Chaves RL, Yong CL, Nehmiz G, Steinmann GG.

Gastroenterology. 2004 Nov;127(5):1347-55.

PMID:
15521004
16.

Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.

Tatami S, Yamamura N, Sarashina A, Yong CL, Igarashi T, Tanigawara Y.

Drug Metab Pharmacokinet. 2004 Feb;19(1):15-23.

18.

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M.

Nature. 2003 Nov 13;426(6963):186-9. Epub 2003 Oct 26. Erratum in: Nature. 2003 Nov 20;246.

19.

Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJ, Peppelenbosch MP, van der Poll T.

J Immunol. 2002 Apr 15;168(8):4070-7.

20.

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.

Sabo JP, Lamson MJ, Leitz G, Yong CL, MacGregor TR.

AAPS PharmSci. 2000;2(1):E1.

21.

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW.

Antimicrob Agents Chemother. 1997 Dec;41(12):2670-9.

22.

Pharmacokinetics and clinical effects of oxybutynin in geriatric patients.

Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong CL.

J Urol. 1988 Jul;140(1):47-50.

PMID:
3379694
23.

Lack of effect of sucralfate on prednisone bioavailability.

Gambertoglio JG, Romac DR, Yong CL, Birnbaum J, Lizak P, Amend WJ Jr.

Am J Gastroenterol. 1987 Jan;82(1):42-5.

PMID:
3799579
24.

Liquid chromatographic determination of propoxyphene and norpropoxyphene in plasma and breast milk.

Kunka RL, Yong CL, Ladik CF, Bates TR.

J Pharm Sci. 1985 Jan;74(1):103-4.

PMID:
3981406
25.

Factors affecting the plasma protein binding of verapamil and norverapamil in man.

Yong CL, Kunka RL, Bates TR.

Res Commun Chem Pathol Pharmacol. 1980 Nov;30(2):329-39.

PMID:
7444161
26.

A simple ultrasound method to characterize in vitro plaque inhibition activity.

Lim JK, Yong CL, Gerencser VF.

J Dent Res. 1979 Feb;58(2):665-9.

PMID:
283099

Supplemental Content

Support Center